14 Fresh A Landscape Of Pharmacogenomic Interactions In Cancer

a landscape of pharmacogenomic interactions in cancer Analysis Defines a Landscape of Pharmacogenomic Interactions For pan cancer ANOVA the set of CFEs included 267 CGs 407 RACSs and three gene fusions a landscape of pharmacogenomic interactions in cancer 8674 16 30746 2 code cell siteThe majority of CFE drug interactions was exclusively identified in either the pan cancer or cancer specific analysis n 662 of 688 significant interactions 96 and n 254 of 262 significant large effect interactions 97 with few overlapping interactions Figure 4A Table S4C

8674 16 30746 2 pdf code cell site PDF fileResource A Landscape of Pharmacogenomic Interactions in Cancer Graphical Abstract Highlights d We integrate heterogeneous molecular data of 11 289 tumors and 1 001 cell lines d We measure the response of 1 001 cancer cell lines to 265 anti cancer drugs d We uncover numerous oncogenic aberrations that sensitize to an anti cancer drug a landscape of pharmacogenomic interactions in cancer we report how cancer driven alterations identified in 11 289 tumors from 29 tissues integrating somatic mutations copy number alterations DNA methylation and gene expression can be mapped onto 1 001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy These results suggest potential roles of clock genes as markers for particular cancer subtypes Interactions between Clinically Actionable Genes and Clock Genes

A Landscape of Pharmacogenomic Interactions in Cancer ANOVA Analysis Defines a Landscape of Pharmacogenomic Interactions For pan cancer ANOVA the set of CFEs included 267 CGs 407 RACSs and three gene fusions BCR ABL EWSR1 FLI1 and EWSR1 X a landscape of pharmacogenomic interactions in cancer Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy These results suggest potential roles of clock genes as markers for particular cancer subtypes Interactions between Clinically Actionable Genes and Clock Genes studies of cancer genomes have provided unprecedented insights into the molecular nature of cancer Using this information to guide the development and application of therapies in the